These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 15114270

  • 1. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B, Zalewska A, Sysa-Jedrzejowska A.
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S, Remitz A, Varga J, Ceska M, Effenberger F, Jimenez S, Uitto J.
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [Abstract] [Full Text] [Related]

  • 7. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
    Hasegawa M, Fujimoto M, Kikuchi K, Takehara K.
    J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
    [Abstract] [Full Text] [Related]

  • 8. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K.
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W, Mastej K, Adamiec R.
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, Cugno M, Bottasso B, Stabilini R.
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Elevated circulating CD40L concentrations in patients with systemic sclerosis.
    Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K.
    J Rheumatol; 2004 Mar; 31(3):514-9. PubMed ID: 14994397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.